Research programme: pluripotent stem cell therapy - Cynata Therapeutics

Drug Profile

Research programme: pluripotent stem cell therapy - Cynata Therapeutics

Alternative Names: Cymerus™ MSC

Latest Information Update: 10 Jul 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Cynata Therapeutics
  • Developer Cynata Therapeutics; Monash University; Royal College of Surgeons
  • Class Antiasthmatics; Antiulcers; Skin disorder therapies; Stem cell therapies
  • Mechanism of Action Cell replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Preclinical Asthma; Diabetic foot ulcer; Sepsis

Most Recent Events

  • 02 Jul 2018 Cynata Therapeutics and Royal College of Surgeons in Ireland enter a partnership to develop mesenchymal stem cell therapy for Sepsis
  • 02 Jul 2018 Preclinical trials in Sepsis in Ireland and Australia (IV)
  • 01 Jun 2018 Preclinical trials in Diabetic foot ulcer in Australia (Topical)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top